Clinical trialPhase 2

NCT04867616. Bepranemab (UCB0107) in prodromal to mild Alzheimer's disease

NCT04867616

Completed phase 2 trial sponsored by UCB Biopharma SRL. Primary completion 24 May 2024. The Lancet Neurology report (PMID 43008775) says the CDR-SB primary endpoint was not met.

1 news item

News about this trial

Scales

Identifiers

NCT
NCT04867616

Original sources

Details

Phase
Phase 2
Status
Completed

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.